RPRX Royalty Pharma plc - Class A

  1. Stocks
  2. Healthcare
  3. NASDAQ: RPRX

Price (delayed)

$68.95

Market cap

$39.55B

P/E Ratio

45.07

Dividend/share

$0.93

EPS

$1.53

Enterprise value

$47.62B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 76
Highlights
The revenue has increased by 11% YoY and by 3.2% from the previous quarter
Royalty Pharma's gross profit has increased by 11% YoY and by 3.2% from the previous quarter
The company's quick ratio has shrunk by 63% YoY and by 54% QoQ
The P/E is 59% higher than the last 4 quarters average of 28.7
Sector: Healthcare
Industry: Biotechnology
Peers: ANIP ABT LLY

Key stats

What are the main financial stats of RPRX

RPRX stock price

How has the Royalty Pharma stock price performed over time
Intraday
-1.51%
1 week
2.04%
1 month
19.33%
1 year
74.16%
YTD
78.44%
QTD
18.15%

Financial performance

How have Royalty Pharma's revenue and profit performed over time
Revenue
$2.62B
Gross profit
$2.62B
Operating income
$1.5B
Net income
$671.45M
Gross margin
100%
Net margin
25.7%
Royalty Pharma's net margin has decreased by 21% YoY and by 20% QoQ
The net income has contracted by 17% from the previous quarter and by 12% YoY
The operating margin has declined by 12% year-on-year and by 4.2% since the previous quarter
The revenue has increased by 11% YoY and by 3.2% from the previous quarter

Price vs fundamentals

How does RPRX's price correlate with its fundamentals

Growth

What is Royalty Pharma's growth rate over time

Valuation

What is Royalty Pharma stock price valuation
RPRX P/E details
P/E
45.07
P/B
4.05
P/S
11.75
EV/EBIT
45.64
EV/EBITDA
45.64
EV/Sales
18.2
The P/E is 59% higher than the last 4 quarters average of 28.7
Royalty Pharma's EPS has decreased by 18% QoQ and by 13% YoY
RPRX's P/B is 87% above its 5-year quarterly average of 2.2 and 37% above its last 4 quarters average of 3.0
The P/S is 73% above the 5-year quarterly average of 6.9 and 36% above the last 4 quarters average of 8.8
The revenue has increased by 11% YoY and by 3.2% from the previous quarter

Efficiency

How efficient is Royalty Pharma business performance
The ROA has decreased by 19% YoY and by 17% from the previous quarter
RPRX's ROE is down by 18% from the previous quarter and by 13% YoY
Royalty Pharma's return on sales has decreased by 14% QoQ and by 10% YoY
The ROIC is down by 9% QoQ and by 7% YoY

Dividends

What is RPRX's dividend history
Dividend details
DPS
$0.93
Dividend yield
1.34%
Payout ratio
60.5%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Royalty Pharma financials performed over time
Royalty Pharma's total assets is 101% more than its total liabilities
The current ratio has dropped by 63% year-on-year and by 54% since the previous quarter
The company's quick ratio has shrunk by 63% YoY and by 54% QoQ
Royalty Pharma's debt is 12% lower than its equity
The debt to equity has decreased by 5% YoY and by 4.3% QoQ
Royalty Pharma's debt has decreased by 4.2% QoQ and by 4% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.